| Name | Title | Contact Details |
|---|
Nexus operates 6 residential treatment sites with programming accredited by COA or TJC, and year-round, on-site schools, as well as inpatient psychiatric care programs, foster care and adoption, in-home counseling services, and ongoing support. Our programs offer a continuum of services to provide boys and girls a safe place to face their past and begin their future. We operate sites and services in Minnesota, Illinois, Maryland, North Dakota, and Idaho, each offering specialized treatment options for your child`s or adolescent`s needs. Mille Lacs Academy Gerard Academy Nexus Glen Lake Indian Oaks Academy Onarga Academy Woodbourne Center Kindred Family Focus PATH North Dakota PATH Idaho
MedeAnalytics provides evidence-based insights to solve a real problem that plagues health care – how to use the immense amount of patient data collected along the care continuum to deliver cost – effective care and promote a healthier population. The platform delivers intelligence that helps healthcare organizations detect their greatest areas of risk and identify opportunities to improve their financial health. It empowers providers and health plans to collaborate and use data to strengthen their operations and improve the quality of care. MedeAnalytics` cloud-based tools have been used to analyze more than 21 billion patient encounters in the United States and United Kingdom, providing better care to more than 30 million patients and better business for 900 healthcare organizations.
NP Medical Inc is a Clinton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Promises Behavioral Health is a company that provides addiction and mental health treatment at treatment facilities across the country.
lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.